Compare Novartis with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs NATCO PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS NATCO PHARMA NOVARTIS/
NATCO PHARMA
 
P/E (TTM) x 674.9 17.0 3,964.7% View Chart
P/BV x 20.3 2.7 755.7% View Chart
Dividend Yield % 2.2 1.3 173.2%  

Financials

 NOVARTIS   NATCO PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
NATCO PHARMA
Mar-19
NOVARTIS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs980849 115.4%   
Low Rs600557 107.8%   
Sales per share (Unadj.) Rs198.7573.8 34.6%  
Earnings per share (Unadj.) Rs21.0176.0 11.9%  
Cash flow per share (Unadj.) Rs22.3198.2 11.2%  
Dividends per share (Unadj.) Rs10.006.25 160.0%  
Dividend yield (eoy) %1.30.9 142.4%  
Book value per share (Unadj.) Rs307.5842.7 36.5%  
Shares outstanding (eoy) m24.6936.50 67.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.01.2 324.5%   
Avg P/E ratio x37.74.0 943.4%  
P/CF ratio (eoy) x35.53.5 1,000.8%  
Price / Book Value ratio x2.60.8 308.0%  
Dividend payout %47.73.6 1,343.0%   
Avg Mkt Cap Rs m19,50825,660 76.0%   
No. of employees `0000.65.0 11.7%   
Total wages/salary Rs m1,1713,559 32.9%   
Avg. sales/employee Rs Th8,445.44,225.3 199.9%   
Avg. wages/employee Rs Th2,015.7718.0 280.7%   
Avg. net profit/employee Rs Th891.01,295.9 68.8%   
INCOME DATA
Net Sales Rs m4,90720,945 23.4%  
Other income Rs m7831,302 60.1%   
Total revenues Rs m5,68922,247 25.6%   
Gross profit Rs m1237,948 1.5%  
Depreciation Rs m32810 3.9%   
Interest Rs m16193 8.2%   
Profit before tax Rs m8588,247 10.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3401,823 18.7%   
Profit after tax Rs m5186,424 8.1%  
Gross profit margin %2.537.9 6.6%  
Effective tax rate %39.622.1 179.3%   
Net profit margin %10.630.7 34.4%  
BALANCE SHEET DATA
Current assets Rs m8,05523,472 34.3%   
Current liabilities Rs m1,8507,287 25.4%   
Net working cap to sales %126.477.3 163.6%  
Current ratio x4.43.2 135.2%  
Inventory Days Days4592 48.8%  
Debtors Days Days3488 38.4%  
Net fixed assets Rs m15018,648 0.8%   
Share capital Rs m123365 33.8%   
"Free" reserves Rs m7,46934,525 21.6%   
Net worth Rs m7,59230,760 24.7%   
Long term debt Rs m00-   
Total assets Rs m9,82443,031 22.8%  
Interest coverage x54.943.7 125.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 102.6%   
Return on assets %5.415.4 35.3%  
Return on equity %6.820.9 32.7%  
Return on capital %11.527.4 41.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5811,536 0.5%   
Fx outflow Rs m1,3262,939 45.1%   
Net fx Rs m-1,2698,597 -14.8%   
CASH FLOW
From Operations Rs m-1,9436,688 -29.0%  
From Investments Rs m2,742-6,122 -44.8%  
From Financial Activity Rs m-298-509 58.6%  
Net Cashflow Rs m50166 759.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 2.0 7.8 25.5%  
FIIs % 1.6 16.6 9.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 26.0 82.7%  
Shareholders   41,647 25,395 164.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SHASUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Volatility, RBI Policy Meet Takeaways, and Top Cues in Focus Today(Pre-Open)

It was a volatile day for India share markets on Friday. The benchmark indices opened higher but turned volatile.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Mar 27, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS